NR4A1 and breast carcinoma: Background parenchymal enhancement (BPE) is a controversial topic, though studies have shown its potential use for breast cancer risk stratification [55,56,57,58,59,60], breast cancer hormonal receptor status [61,62,63], and cancer treatment response [64,65].